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Transactivation of human 
osteoprotegerin promoter by 
GATA-3
Shyan-Yuan Kao1 & Konstantina M. Stankovic1,2
Osteoprotegerin (OPG) is a key regulator of bone remodeling. Mutations in OPG are involved in a 
variety of human diseases. We have shown that cochlear spiral ganglion cells secrete OPG at high 
levels and lack of OPG causes sensorineural hearing loss in addition to the previously described 
conductive hearing loss. In order to study the regulation of OPG expression, we conducted a 
database search on regulatory elements in the promoter region of the OPG gene, and identified 
two potential GATA-3 binding sites. Using luciferase assays and site directed mutagenesis, we 
demonstrate that these two elements are GATA-3 responsive and support GATA-3 transactivation in 
human HEK and HeLa cells. The expression of wild type GATA-3 activated OPG mRNA and protein 
expression, while the expression of a dominant negative mutant of GATA-3 or a GATA-3 shRNA 
construct reduced OPG mRNA and protein levels. GATA-3 deficient cells generated by expressing a 
GATA-3 shRNA construct were sensitive to apoptosis induced by etoposide and TNF-α. This apoptotic 
effect could be partly prevented by the co-treatment with exogenous OPG. Our results suggest 
new approaches to rescue diseases due to GATA-3 deficiency – such as in hypoparathyroidism, 
sensorineural deafness, and renal (HDR) syndrome – by OPG therapy.
Osteoprotegerin (OPG) is a member of the tumor necrosis factor (TNF) receptor superfamily and a key 
regulator of bone metabolism. OPG acts as a soluble, neutralizing antagonist that competes with recep-
tor activator of nuclear factor-κ B (RANK) on preosteoclasts and osteoclasts for RANK ligand (RANKL) 
produced by osteoblasts. The discovery of the RANKL/RANK/OPG signaling and its role in the regu-
lation of bone resorption, osteoclast formation, and skeletal remodeling represents a major advance in 
bone biology1. Using transgenic mice overexpressing OPG and rats injected with OPG, OPG has been 
shown to inhibit osteoclastogenesis in vivo2,3. OPG null mice displayed decreased total bone density 
and early-onset, severe osteoporosis accompanied with vascular calcification4,5, indicating that OPG is a 
negative regulator of osteoclastogenesis.
Besides RANKL, OPG is known to interact with another TNF family member, the TNF-related apop-
tosis inducing ligand (TRAIL). TRAIL can bind to its transmembrane receptors (death receptors: DR4 
and DR5) to induce apoptosis in cancer cells6–8. OPG secreted by tumor cells or bone marrow stromal 
cells can efficiently bind to TRAIL and block its pro-apoptotic activity in a variety of tumor cell lines6–8. 
In addition to promoting cancer cell survival, OPG can induce angiogenesis9. Elevated OPG serum lev-
els have been detected in patients with advanced malignancies such as prostate cancer10, bladder car-
cinoma11, and squamous cell head and neck cancer12. These observations confirm the role of OPG in 
tumor development.
We have shown that OPG null mice develop sensorineural hearing loss due to degeneration of spiral 
ganglion neurons13, in addition to the previously reported conductive hearing loss due to resorption of 
the bony ossicles in the middle ear14. Given the important roles of OPG in hearing, bone physiology, 
1Eaton Peabody Laboratories and Department of Otolaryngology, Massachusetts Eye and Ear Infirmary. 
2Department of Otology and Laryngology, and Program in Speech and Hearing Bioscience and Technology, 
Harvard Medical School, Boston, Massachusetts, USA. Correspondence and requests for materials should be 
addressed to K.M.S. (email: konstantina_stankovic@meei.harvard.edu)
received: 24 March 2015
accepted: 16 June 2015
Published: 28 July 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:12479 | DOi: 10.1038/srep12479
and tumor biology, we studied regulation of OPG expression by focusing on the OPG promoter. Others 
have demonstrated that the two Hox binding sites on human OPG promoter are responsible for bone 
morphogenesis protein (BMP) induced transcription of OPG gene and increased OPG secretion, thus 
inhibiting osteoclastogenesis15. Transforming growth factor-β (TGF-β ) is known to activate human OPG 
promoter through the osteocalcin-specific element 2 (OSE2) and Smad binding element (SBE) sites, 
and this activation by TGF-β may be mediated by the interaction between Cbfa1 and Smad proteins16. 
Overexpression of OPG in human colorectal cancer cells is regulated by β -catenin and Tcf-4 bound to 
the human OPG promoter, thus mediating resistance to TRAIL-induced apoptosis in colon cancer17. 
We have explored OPG regulation by GATA-3, a member of the GATA family of transcription factors18 
which bind to a GATA consensus motif (A/TGATAA/G)19.
We have focused on GATA-3 because mutations or deletions (haploinsufficiency) in the human 
GATA3 gene cause sensorineural hearing loss as a part of the syndrome of hypoparathyroidism, sensori-
neural deafness, and renal disease (HDR syndrome)20–23. Moreover, manipulation of GATA-3 expression 
results in similar bone phenotype as seen when manipulating OPG expression. Specifically, inhibition of 
GATA-3 expression, by introducing GATA3 small interfering RNA (siRNA) into osteoblasts, decreased 
GATA-3 levels and its downstream target bcl-x(L), thus causing apoptosis in osteoblasts24. Conversely, 
overexpression of GATA-3, in a mouse model of rheumatoid arthritis, protected against severe joint 
inflammation and bone erosion25.
GATA3 is highly conserved across vertebrate species. For example, the human and mouse GATA-3 
proteins share a 96% amino acid homology26. GATA-3 is expressed in a variety of tissues in both human 
and mouse27, where it is involved in neuronal cell development and differentiation28, adipocyte differen-
tiation29, T cell development30, skin cell differentiation31, mammary gland morphogenesis and luminal 
cell differentiation32, and lens development33. In addition, aberrant expression of GATA-3 is involved in 
a variety of malignancies in human and mouse models such as thymic lymphoma34, pancreatic cancer35, 
breast cancer36, and bladder cancer37.
We discovered several GATA-3 transcription factor binding sites on the promoter region of human 
OPG gene. The identification of OPG as a potential GATA-3 downstream target suggests that OPG and 
GATA-3 may share similar signaling pathways. This knowledge motivates future studies to determine 
whether exogenous OPG can partially rescue diseases due to GATA3 deficiency such as HDR syndrome, 
and whether the increase of OPG expression by manipulation of GATA3 can prevent diseases such as 
osteoporosis.
Material and Methods
Antibodies and reagents. The rabbit anti-GATA-3 polyclonal antibody (#5852), rabbit anti-cleaved 
caspase 3 (#9579), and the rabbit anti-β -actin polyclonal antibody (#4970) were purchased from Cell 
Signaling Technology (USA), the mouse anti-OPG antibody (ALX-804-532-C100) was from Enzo Life 
Sciences, DNA mutagenesis was performed using the QuikChange™ II Site-Directed Mutagenesis Kit 
(#200521, Agilent, USA) and the luciferase assay was performed using the Dual-Luciferase® Reporter 
Assay System (#E1910, Promega, USA). The DeadEnd™ Fluorometric TUNEL System was purchased 
from Promega (#G3250). The recombinant human osteoprotegerin was from R&D Systems (#185-OS-
025/CF, USA). The apoptosis inducing agents, tumor necrosis factor alpha (TNF-α ) (#8902) and etopo-
side (#341205), were from Cell Signaling and EMD Millipore (USA), respectively.
Plasmids. The green fluorescent protein (GFP) tagged human GATA-3 plasmid, pcDNA-GFP-GATA-3, 
was a gift from Dr. Kwang-Soo Kim (McLean Hospital, Harvard Medical School). The dominant neg-
ative GATA-3 mutant38 was cloned from the wild type GATA-3 using the QuikChange™ Site-Directed 
Mutagenesis Kit to replace the cysteine residue at location 321 into serine. The internal control renilla 
plasmid, pRL-SV40, was purchased from Promega. The OPG promoter construct, pGL-OPG-Luc (pOPG), 
was amplified from HeLa total genomic DNA (Promega) by PCR and cloned into the pGL3 luciferase 
reporter vector, pGL3-basic (#E1751, Promega). The cloned OPG promoter sequence from HeLa cells 
was sequenced and no mutations were identified compared to the published OPG promoter sequence 
(Genebank accession number AY577781). The mutations on the OPG promoter (pmG3RE1, pmG3RE2, 
and pDM plasmids) were introduced using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene). 
The p5xG3RE1Luc and p5xG3RE2Luc were cloned using synthetic oligos. The sequences were shown in 
Figs 1 and 2 (GenBank accession number AY466112). The GATA3 specific shRNA (sc-29331-SH) and 
control shRNA plasmid-A (sc-108060) were from Santa Cruz Biotechnology. pSG5L-HA-RB (#10720, 
Addgene) and pEBB-GFP-hBEN (#22157, Addgene) were used as controls for non-specific transcrip-
tional regulators which did not bind to the GATA-3 binding site.
Luciferase assay. The human embryonic kidney (HEK 293) cells were transfected with the OPG 
promoter reporter, pcDNA-GFP-GATA-3, or pcDNA-dnGATA-3 plasmids together with the pRL-SV40 
(to control for transfection efficiency). Twenty-four hours after transfection, cells were lysed and 
luciferase and renilla activity were measured using a Wallac VICTOR Model 1420 multilabel coun-
ter (PerkinElmer). Luciferase activity was normalized to the renilla activity of the same plate. The fold 
induction was determined as the average of three wells per treatment normalized to the average signal 
of the reporter-alone wells, which was set as 1.
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Chromatin immunoprecipitation. The association between GATA-3 and the OPG promoter was 
assayed by chromatin immunoprecipitation (ChIP) using the ChIP assay protocol described before39 with 
some modifications. HeLa cells transfected with pGFP-GATA-3 or a control plasmid were harvested and 
the amount of DNA in the resulting cell lysates was quantified by measuring absorption at 260 nm; the 
pGL -OPG-Luc
-950
cGATAc (G3RE1)
aGATAa (G3RE2)
GATA-3 responsive element
-575 -570
-713 -708
wtGATA-3 RB1 GTF2IRD1
7
control
noitavitca
dloF
input GFP- GATA-3—
α -GFP α -IgG α -GFP
A
B C
D wt GATA3 958AAC TGT CAG 966
dn GATA3 AAC TCT CAG
320 321 322 aa
Cys → Ser
0
1
2
3
4
5
6
7 *noitavitca
dloF
3-ATAGtw
3-ATAGnd
1BR
1DRI2FTG
wtGATA-33-ATAGnd
lortnoc
-895~-461
-2185~-1873
* *
**
0
1
2
3
4
5
6
Luciferase
Figure 1. Transactivation of the OPG promoter by GATA-3. (A) A schematic diagram of two potential 
GATA-3 responsive elements on the human OPG promoter. The minimal OPG promoter was cloned from a 
HeLa genomic DNA library by PCR and cloned into the pGL-Luc vector. (B) Transactivation of the minimal 
OPG promoter by GATA-3 but neither RB-1 nor GTF2IRD1 using the dual luciferase assay.  
(C) Chromatin immunoprecipitation assay showing the binding of GATA-3 on the OPG promoter. The GFP-
GATA-3 plasmid was transfected into HeLa cells and immunoprecipitated using an anti-GFP antibody. The 
PCR reaction showed that GFP-GATA-3 interacted with the chromatin containing the two potential GATA-3 
responsive elements on the OPG promoter (from − 895 to − 461) but not the fragment outside the potential 
GATA-3 responsive element (from − 2185 to − 1873). (D) A dominant negative GATA-3 mutant lost its 
transactivation activity on the OPG promoter construct and could block the transactivation activity of the 
wild type GATA-3. **p < 0.01, ***p < 0.001, n = 5.
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Figure 2. Identification of GATA-3 responsive elements on OPG promoter. (A) Luciferase results 
showed that mutations in either GATA-3 responsive element on the OPG promoter still supported GATA-3 
transactivation while mutations in both elements blocked GATA-3 transactivation in HeLa cells after 
24 hours of transfection. *p < 0.05, n = 5. (B) The gel shift assay showed that recombined GATA-3 could 
bind to the labeled G3RE1 and G3RE2 probes. This interaction could be blocked by a mutant G3RE1 or 
G3RE2 probe or excess non-labeled G3RE1 or G3RE2 probe. (C) The multiple minimal G3RE1 and G3RE2 
could support GATA-3 transactivation. ** p < 0.01, n = 4.
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DNA concentration was then normalized to 100 μ g/μ l. Supernatant (200 μ g DNA) was diluted 10-fold 
in 2 ml ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 
167 mM NaCl, and protease inhibitors), and precleared twice with BSA-blocked Protein A/G Agarose 
(sc-2003, Santa Cruz) (2 × 100 μ g, 2 × 30 min at 4 °C). The beads were centrifuged and the supernatant 
was divided into 4 × 500 μ l aliquots for immunoprecipitation, input DNA, and the IgG control. Primary 
antibody was added and incubated at 4 °C overnight. A rabbit anti-GFP polyclonal antibody (A6455, 
Invitrogen) was used for immunoprecipitation of GATA-3, and ChromPure rabbit IgG (#011-000-003, 
Jackson ImmunoResearch) was used for the IgG control. Thirty μ l of BSA-blocked Protein A/G Agarose 
was then added and incubated at 4 °C with rotation. The beads were centrifuged and washed once with 
a low salt immune complex buffer (#20–154, Millipore), twice with a high salt wash buffer, once with a 
LiCl wash buffer (#20–156, Millipore), and twice in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
The washed agarose beads were eluted with 2 × 250 μ l freshly prepared elution buffer (1% SDS, 0.1 mM 
NaHCO3). DNA crosslinking was reversed by adding 5 M NaCl and heating at 65 °C for 4 hrs. Protein 
was removed by incubation with 20 mg/ml proteinase K in 10 μ g EDTA/40 mM Tris-HCl, pH 6.5 for 3 
hr at 45 °C. De-crosslinked DNA was isolated by QIAquick PCR purification kit (#28104, Qiagen) and 
ethanol precipitation. The precipitated DNA was washed with 70% ethanol, air dried and dissolved in 
ddH2O for PCR. The amplification product by primers for GATA binding sites in the OPG promoter was 
from − 895 to − 461 of the OPG promoter, and the amplification product by control primers was from 
− 2185 to − 1873 of the OPG promoter.
Real-time quantitative RT-PCR. HEK cells were transfected with wild type GATA-3, dominant neg-
ative GATA-3, empty pcDNA3.1 expressing plasmids, GATA-3 shRNA, or control shRNA plasmid-A.
After 48 h of transfection, total RNA was extracted using RNeasy Mini Kit (#74104, Qiagen) according 
to the manufacturer’s protocol. Total RNA was reverse transcribed with Taqman Reverse Transcription 
Reagents kit (N8080234, Life Technologies). Real-time quantitative RT-PCR (qRT-PCR) was performed 
using 6-FAM linked fluorescent probes and primers for human OPG (#4331182), and GATA-3 (#4331182) 
designed and optimized by Applied Biosystems. The measurements were carried out on the Mx3005P 
machine (Stratagene) using 96 well plates. Fluorescence data were collected starting with a denaturation 
step at 95 °C for 10 minutes, followed by 45 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Gene 
expression levels were quantified relative to the 18 S rRNA gene, and analyzed using the comparative 
threshold cycle method. Previous studies have shown that GATA-3 does not activate 18 S gene40.
Gel shift assay. The gel shift assay was performed using the LightShiftTM EMSA Optimization 
& Control Kit (#20148, Thermo Scientific) according to the manufacturer’s manual. The purified human 
GATA-3 protein was from OriGene. The 6% DNA retardation gels, biotin labeled G3RE1 probe 
(5'-TAGGAAGCTCCGATACCAATAGCCCT-3'), unlabeled G3RE1 probe, unlabeled mutant G3RE1 probe 
(5'-TAGGAAGCTCCCATGGCAATAGCCCT-3'), wild type G3RE2 probe (5'-TAACTACCCCAGATAAG 
AAGGAGTGA-3'), unlabeled wild type G3RE2 probe, and unlabeled mutant G3RE2 probe 
(5'-TAACTACCCCAGAGTTGAAGGAGTGA-3') were synthesized by Invitrogen.
Western blot analysis. Cells were lysed in RIPA-DOC buffer (50 mM Tris buffer (pH 7.2), 
150 mM NaCl, 1% Triton-X100, 1% deoxycholate and 0.1% SDS) with protease inhibitors (cOmplete, 
# 04693132001, Roche Molecular Biochemicals). Equal amount of protein extract was loaded per 
lane, resolved by 4–20% SDS–PAGE, and electro-transferred onto a PVDF membrane (IPVH00010, 
Immobilon-P, Millipore). Detection of proteins by antibodies was performed as described previously41. 
Immunoreactivity was detected with the enhanced chemiluminescence detection kit (#32106, ECL, 
Pierce). Protein bands were quantitated using the ChemiDoc™ XRS+ System. Actin was used as the 
internal control because previous studies have shown that GATA-3 does not activate actin expression17,30.
Enzyme-linked immunosorbent assay (ELISA) for OPG in cell lysate and culture 
medium. Detection of OPG secreted from culture cells was performed using the Human OPG ELISA 
kit (ELH-OPG, RayBiotech) according to the instruction manual. For OPG in cell lysate, cells were first 
suspended in cell lysis buffer (50 mM Tris-HCl (pH 8.0), 150 nm NaCl, 2 mM EDTA, and 1% NP40) fol-
lowed by sonication. For OPG in culture medium, cells were cultured overnight and the culture medium 
was collected for ELISA. The OPG concentration in cell lysate was presented as the amount of OPG 
protein in total cell lysate. The OPG concentration in culture medium was presented as the level of OPG 
concentration in the culture medium per 1000 μ g of cell lysate.
Detection of apoptosis. Cells were pre-treated with OPG (10 μ g/mL) for 2 h followed by co-treatment 
with TNF-α (2 μ g/mL) or etoposide (10 μ M) overnight. For detection of cleaved caspase 3, cells were 
harvested for western blot analysis as described above, and the rabbit anti-caspase 3 antibody (Cell 
Signaling) was used. For terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, 
cells were fixed with 4% paraformaldehyde after treatment and the assay was performed according to the 
operation manual of the DeadEnd™ Fluorometric TUNEL System (G3250, Promega).
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Statistical analysis. Data were presented as mean ± standard deviation and analyzed using Excel 
(Microsoft). Data within a group were compared using the paired t test and data between groups were 
compared using the analysis of variance. Differences were considered significant if p < 0.05.
Results
Transactivation of the OPG promoter by GATA-3. To study the regulation of the human OPG 
expression, the human OPG promoter was analyzed using several on-line promoter and transcription 
factor analysis tools including Tfsitescan (http://www.ifti.org/Tfsitescan/) and PROMO (http://alggen.lsi.
upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB= TF_8.3. The common feature of these analyses 
was identification of two potential GATA-3 binding sites on human OPG promoter at − 713 to − 708 
(which we named GATA-3 responsive 1, G3RE1) and − 575 to − 570 (which we named G3RE2) (GenBank 
accession number: AY466112) (Fig. 1A). To test whether these two putative GATA-3 responsive elements 
on the OPG promoter could support GATA-3 transactivation, we cloned the promoter sequence from the 
HeLa total genomic DNA into the luciferase reporter vector pGL-basic. Luciferase assays were performed 
to determine the ability of GATA-3 to activate the OPG promoter. The GATA-3 transactivated the OPG 
promoter 5.61 ± 0.79 fold (n = 5, p = 0.002), while the control transcriptional factors, retinoblastoma 1 
(RB1) and general transcription factor II-I repeat domain-containing protein 1 (GTF2IRD1), which do 
not bind to the GATA-3 binding site, did not activate the OPG promoter (Fig. 1B).
To further validate the transactivation ability of GATA-3 on OPG promoter, a ChiP assay was per-
formed. The chromatin fragment of the OPG promoter region from − 895 ~ − 461, containing both the 
G3RE1 and G3RE2 sites, could be immunoprecipitated by the GFP antibody after transfection with 
the pGFP-GATA-3 plasmid (Fig.  1C, top). In the control, the chromatin fragment of the OPG pro-
moter without GATA-3 binding sites (from − 2185 to − 1873) could not be immunoprecipitated when 
the pGFP-GATA-3 plasmid was transfected (Fig. 1C, bottom). These results suggest that GATA-3 could 
transactivate the human OPG promoter through the two GATA-3 binding sites.
To further test the specificity of the GATA-3 binding sites, a GATA-3 dominant negative mutant was 
cloned using the PCR mutagenesis method. The GATA-3 dominant negative mutant (dnGATA-3) was 
discovered in an HDR patient, which had a cysteine to serine mutation at the position of amino acid 321 
(Fig. 1D, top)38. The dnGATA-3 lacked transactivation activity due to the loss of DNA binding activity 
and disrupted the transactivation activity of the wild type GATA-3 (wtGATA-3). The luciferase results 
showed that the dnGATA-3 failed to transactivate the OPG promoter and blocked the transactivation 
activity of wtGATA-3 with the OPG promoter when wtGATA-3 and dnGATA-3 were co-transfected with 
the OPG promoter reporter (n = 5, p = 0.0007). The control RB1 and GTF2IRD1 proteins had little effect 
on the transactivation activity of the wtGATA-3 (Fig. 1D, bottom).
Characterization of minimal GATA-3 responsive elements on the OPG promoter. To deter-
mine whether the two putative GATA-3 binding sites on the OPG promoter were true GATA-3 binding 
sites, several mutations were introduced into the distal site, proximal site, or both sites to make the 
pmG3RE1, pmG3RE2, and pDM plasmids, respectively (Fig.  2A, top). The luciferase results showed 
that mutations on either binding site did not significantly disrupt the transactivation by the wtGATA-3 
(p = 0.83 for pmG3RE1 and p = 0.28 for pmG3RE2 compared to pOPG; n = 5) (Fig.  2A). However, 
mutations at both sites, pDM, significantly decreased the transactivation by the wtGATA3 (p = 0.03). 
These results suggest that these two GATA-3 binding sites have redundant GATA-3 binding function so 
that loss of both precludes binding.
To further demonstrate that G3RE1 or G3RE2 alone could support GATA-3 transactivation, the gel 
shift assay was performed. When incubating the biotin-labeled probes containing either G3RE1 or G3RE2 
with the HeLa nuclear extract, a specific band was observed (Fig. 2B, lane 2 and lane 6). This band disap-
peared by adding excess un-labeled G3RE1 or G3RE2 probes (Fig. 2B, lane 3 and lane 7) but not by add-
ing excess cold (non-labeled) mutant G3RE1 or G3RE2 probes (Fig. 2B, lane 4 and lane 8). These results 
suggest that the G3RE1 and G3RE2 probe could bind GATA3 protein in HeLa nuclear extract. In order 
to further support that these minimal elements could support GATA-3 activation, we constructed two 
reporter plasmids with minimal 5-fold GATA-3 responsive element, p5xG3RE1Luc and p5xG3RE2Luc 
(Fig. 2C, top). A luciferase assay showed that these two constructs with minimal GATA-3 responsive ele-
ments from the OPG promoter supported GATA-3 transactivation (Fig. 2C, bottom) by increasing activ-
ity 4.70 ± 0.34 fold for G3RE1 (p = 0.0016, n = 4) and 4.50 ± 0.61 fold for G3RE2 (p = 0.01, n = 4). The 
activation of the two constructs with minimal GATA-3 responsive elements by wtGATA-3 could be dis-
rupted by the co-transfection of the dominant negative GATA-3 mutant (p = 0.001 and 0.01, respectively, 
n = 4), further indicating that GATA-3 transactivates the OPG promoter through these two elements.
Regulation of the expression of the OPG gene and protein by GATA-3. The effect of GATA-3 on 
the expression of the OPG gene and protein in vivo was investigated using the qRT-PCR (Fig. 3A,B) and 
western blot analysis (Fig. 3C). HEK cells were transfected with the wtGATA-3 plasmid, the dnGATA-3 
plasmid, GATA-3 shRNA, scrambled shRNA, or an empty vector. Forty-eight hours after transfection, 
cells were harvested, and total RNA (n = 3 different cultures) or total protein (n = 3 different cultures) 
was isolated. The qRT-PCR results showed that overexpression of wtGATA-3 increased the expression of 
the endogenous OPG mRNA 126.24 ± 4.84 fold (p = 0.0001), while the overexpression of the dnGATA-3 
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reduced the expression of OPG mRNA by 0.5297 ± 0.18 fold (p = 0.022) relative to controls (set at 1) 
transfected with the empty vector (Fig. 3A). The transfection of GATA-3 shRNA reduced the expression 
of endogenous GATA-3 mRNA (0.067 ± 0.004, p = 0.0034) and OPG (0.199 ± 0.35, p = 0.042). The trans-
fection of scrambled shRNA had no statistically significant effect on the expression of endogenous GATA-
3 mRNA (1.036 ± 0.021, p = 0.15) or OPG mRNA (1.7144 ± 1.05, p = 0.32) (Fig.  3B). At the protein 
level, the expression of endogenous OPG in cultured HeLa cells increased 1.83 ± 0.32 fold (p = 0.003) 
after overexpression of the wild type GATA-3, while the expression of OPG was reduced by 0.85 ± 0.10 
fold (p = 0.033) following the overexpression of the dominant negative GATA-3 compared to controls (set at 
1) (Fig. 3C). These results indicate that, in addition to activating the minimal OPG promoter construct, 
GATA-3 also activated the expression of the endogenous OPG mRNA and protein.
To further quantify the level of OPG expression in cultured cells and their secretions, ELISA was 
applied to cell lysates and conditioned culture medium after transfecting cells with the wtGATA-3, 
dnGATA-3, or a GATA-3 specific shRNA (Fig. 3D). Because the level of OPG secretion from HeLa cells 
was higher than the highest OPG standard in the ELISA kit, it was difficult to compare the differences 
after transfection with either wtGATA-3 or dnGATA-3 expressing plasmids. Therefore, we used HEK-293 
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Figure 3. Regulation of endogenous OPG mRNA and protein by GATA-3. (A) wtGATA-3 and dnGATA-3 
expression plasmids were transfected into HEK cells and the expression of GATA-3 and OPG mRNA was 
measured using qRT-PCR. (B) GATA-3 and scrambled shRNA constructs were transfected into HEK cells 
and GATA-3 and OPG mRNA expression after 48 h was measured using qRT-PCR. (C) wtGATA-3 and 
dnGATA-3 expression plasmids were transfected into HEK cells and the expression of GATA-3 and OPG 
proteins was detected using western blot analysis.(D) OPG secretion from HEK cells transfected with either 
the wtGATA-3 or dnGATA-3 plasmid for 48 h were measured in cell-conditioned culture medium using 
ELISA. *p < 0.05, **p < 0.01, n = 3 for qRT-PCR and western blot and n = 4 for ELISA. Full-length blots are 
presented in supplementary Figure 1.
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cells whose baseline secretion of OPG was 1.42 ± 0.31 pg/ml per 1 mg cell lysate (n = 4 different cultures). 
After transfection with the wtGATA-3 expressing plasmid, the level of OPG expression increased to 
2.08 ± 0.26 pg/ml per 1 ml cell lysate (p = 0.02). In contrast, the transfection of dnGATA-3 expressing 
plasmid reduced the level of OPG expression to 0.94 ± 0.21 pg/ml per 1 ml cell lysate (p = 0.01). These 
results further confirm that OPG is a target gene for GATA-3.
Regulation of cell death by GATA-3 and OPG. To study the effect of activation of OPG by GATA-3, 
a GATA-3 deficient HEK cell line was established by introducing a GATA-3 specific shRNA. The expres-
sion of the shRNA construct reduced the expression of GATA-3 protein in HEK cells, which resulted in 
the reduction of OPG protein expression (Fig. 4A, bottom left). Compared with the control cells which 
expressed the control scrambled shRNA plasmid (Fig.  4A, left), the GATA-3 shRNA expressing cells 
exhibited a higher level of cell death, as shown in the increased expression of cleaved caspase 3 protein in 
the western blot analysis (Fig. 4A, left, column 3 versus 1). When treated with etoposide, a topoisomerase 
inhibitor that induces apoptotic cell death, the level of cell death in the GATA-3 shRNA expressing cells 
was even more evident compared with that in the control cells (Fig. 4A, left, column 4 versus 2). These 
results indicate that GATA-3 deficient cells were more prone to apoptotic cell death. This increased cell 
death in GATA-3 shRNA expressing cells could be suppressed by the addition of exogenous recombinant 
OPG protein (Fig. 4A, right). The cell death induced by etoposide in GATA-3 deficient cells could also 
be suppressed by OPG (Fig. 4A, right).
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Figure 4. Regulation of apoptosis by GATA-3 and OPG. (A) HEK cells expressing either a scrambled 
shRNA or a GATA-3 shRNA expressing plasmid were treated with etoposide (10 μ M), and apoptosis was 
assayed by Western blot (left). HEK cells expressing a GATA-3 shRNA expressing plasmid were treated with 
purified OPG protein for 2 h before treatment with etoposide, and apoptosis was assayed by Western blot 
(right). Full-length blots are presented in supplementary Figure 1. (B) HEK cells expressing either a control 
plasmid or a GATA-3 shRNA expressing plasmid were treated with TNF-α (2 μ g/mL) with or without pre-
treatment with OPG for 2 h. Subsequent cell death was measured using TUNEL assays (left), and quantified 
with bar graphs (right). *p < 0.05, n = 3.
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To further confirm that cell death mediated by GATA-3 deficiency could be suppressed by the addi-
tion of the exogenous recombinant OPG proteins, a different apoptosis inducing agent and a differ-
ent apoptosis detection method were used. The TUNEL assay showed that without treatment, the level 
of cell death in GATA-3 shRNA expressing cells (8.17 ± 0.82%) was higher than that in the control 
cells (5.19 ± 1.85%) (Fig.  4B, p = 0.044). The difference in the levels of cell death was enhanced when 
cells were treated with TNF-α (Fig. 4B), raising the levels from from 16.38 ± 2.52% in the control cells 
to 24.30 ± 2.63 in the GATA-3 shRNA treated cells (p = 0.045) . The increased levels of cell death in 
GATA-3 deficient cells could be suppressed to 18.20 ± 1.2 (p = 0.04) by the addition of recombinant OPG 
protein (Fig. 4B), suggesting that OPG is a downstream molecule of GATA-3, and that OPG can partially 
rescue the function of GATA-3 deficiency.
Discussion
Using a variety of molecular approaches, including site directed mutagenesis and cell transfection with 
mutant GATA-3 constructs, we have shown for the first time that GATA-3 transactivates the human OPG 
promoter. Although we have focused on cell lines in these mechanistic studies, our results have implica-
tions for a variety of physiologic and pathologic processes that involve OPG and GATA-3.
We are particularly interested in our findings’ implication for bone metabolism and sensorineural 
hearing loss. With regard to bone metabolism, our results provide insight into the observed similarity of 
bone phenotypes due to OPG deficiency and GATA-3 deficiency. Specifically, OPG null mice have severe 
osteoporosis due to increased osteoclastogenesis4,5 whereas GATA-3 inhibition in osteoblasts induces 
their apoptosis24. Conversely, exogenous OPG can successfully treat osteoporosis42 whereas GATA-3 
overexpression protects against bone erosion in arthritis24. These observations, in light of our findings, 
suggest a mechanism for overlapping functions of GATA-3 and OPG.
Our results may also shed light on the unclear mechanism of sensorineural hearing loss due to 
GATA-3 deficiency in HDR syndrome. Sensorineural hearing loss in HDR syndrome occurs at birth 
and is bilateral21. Histopathology of the human inner ear has not been described in HDR syndrome. 
However, a critical role of GATA-3 in the development of the mammalian inner ear and auditory neurons 
has been demonstrated in animal models43–45. GATA-3 is expressed in the murine optic placode as early 
as embryonic day 9 (E9)43, and it is expressed in both sensory and nonsensory cells, including cells in the 
developing cochlear duct and spiral ganglion44. Expression of GATA-3 in the organ of Corti and spiral 
ganglion persists throughout adulthood44. Gata3 haploinsufficiency in mice causes progressive degen-
eration of hair cells, supporting cells, and spiral ganglion neurons in the cochlea, which is reflected in 
physiologic metrics of elevated auditory brainstem response thresholds and decreased distortion product 
otoacoustic emissions44,46. Loss of GATA-3 expression also causes limited morphogenesis and neurosen-
sory development, altered inner ear innervation, and reduced projection of vestibulo-cochlear efferents 
in the murine cochlea47. GATA-3 controls prosensory domain specification and regulates survival of 
spiral ganglion neurons in the murine cochlea48. GATA-3 is considered an “intermediate regulator” of 
spiral ganglion neuron differentiation, and is critical for cochlear wiring49.
Despite the important role of the transcription factor GATA-3 in inner ear development and func-
tion, the downstream targets of GATA-3 in the inner ear or cochlear neurons have not been identified. 
Although several studies have attempted this identification40,50, the target genes of GATA-3 in the cochlea 
are not fully elucidated. In this study, we identified two GATA-3 responsive elements on the OPG pro-
moter, and demonstrated regulation of OPG expression by GATA-3. These results may provide insight 
into the function of GATA-3 and OPG in the cochlea. OPG is present at exceptionally high levels in 
cochlear fluids and tissues compared to those in cerebrospinal fluid (CSF), serum and bone51 – the 
finding that was unexpected as previous studies had focused on the role of OPG in bone development. 
Mice lacking functional OPG develop progressive hearing loss52. We have shown that this hearing loss 
is due not only to abnormalities in the bone surrounding the inner ear but, even more importantly, to 
the degeneration of spiral ganglion neurons13. These neurons highly express and secrete OPG. We have 
also shown that OPG is important for the proliferation and survival of inner ear stem cells13. These OPG 
functions in the cochlea overlap with GATA-3 functions in the same tissues. These published results – 
combined with our current findings of transactivation of OPG promoter by GATA-3 and partial rescue 
of cell death mediated by reduced GATA-3 expression by OPG overexpression – strongly motivate future 
experiments to determine whether OPG can partially rescue hearing loss due to GATA-3 deficiency, as 
seen in HDR syndrome.
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